55.05
1.98%
-1.11
After Hours:
55.03
-0.02
-0.04%
CRISPR Therapeutics AG stock is currently priced at $55.05, with a 24-hour trading volume of 1.76M.
It has seen a -1.98% decreased in the last 24 hours and a -23.50% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $56.48 pivot point. If it approaches the $54.93 support level, significant changes may occur.
CRISPR Therapeutics AG Stock (CRSP) Financials Data
CRISPR Therapeutics AG (CRSP) Revenue 2024
CRSP reported a revenue (TTM) of $170.10 million for the quarter ending June 30, 2023, a +1,207% rise year-over-year.
CRISPR Therapeutics AG (CRSP) Net Income 2024
CRSP net income (TTM) was -$153.61 million for the quarter ending December 31, 2023, a +76.37% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Cash Flow 2024
CRSP recorded a free cash flow (TTM) of -$272.35 million for the quarter ending December 31, 2023, a +48.90% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Earnings per Share 2024
CRSP earnings per share (TTM) was -$1.93 for the quarter ending December 31, 2023, a +76.94% growth year-over-year.
CRISPR Therapeutics AG Stock (CRSP) Latest News
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Zacks Investment Research
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
Zacks Investment Research
3 Magnificent Stocks That Could Double or More by 2030
The Motley Fool
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Zacks Investment Research
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:
|
Volume (24h):